Bellicum Pharmaceuticals (BLCM) Rating Increased to Buy at BidaskClub
Bellicum Pharmaceuticals (NASDAQ:BLCM) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.
A number of other brokerages have also recently commented on BLCM. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Zacks Investment Research cut shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, January 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price target (down from $12.00) on shares of Bellicum Pharmaceuticals in a research report on Wednesday, January 31st. Wells Fargo cut shares of Bellicum Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.00 price target on the stock. in a research report on Wednesday, January 31st. Finally, Citigroup increased their price target on shares of Bellicum Pharmaceuticals from $24.00 to $27.00 and gave the company a “hold” rating in a research report on Friday, February 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $17.98.
BLCM stock opened at $8.97 on Tuesday. The company has a current ratio of 8.37, a quick ratio of 8.37 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $301.48, a P/E ratio of -3.16 and a beta of 0.47. Bellicum Pharmaceuticals has a 1-year low of $5.02 and a 1-year high of $14.49.
In other news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $8.63, for a total value of $2,248,978.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 18.77% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of the company. MYDA Advisors LLC bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth approximately $118,000. Cubist Systematic Strategies LLC bought a new position in shares of Bellicum Pharmaceuticals in the third quarter worth approximately $164,000. LPL Financial LLC bought a new position in shares of Bellicum Pharmaceuticals in the fourth quarter worth approximately $140,000. Goldman Sachs Group Inc. grew its holdings in shares of Bellicum Pharmaceuticals by 14.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 148,860 shares of the biopharmaceutical company’s stock worth $1,252,000 after purchasing an additional 19,257 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Bellicum Pharmaceuticals by 28.3% in the fourth quarter. Deutsche Bank AG now owns 110,028 shares of the biopharmaceutical company’s stock worth $924,000 after purchasing an additional 24,246 shares during the last quarter. Hedge funds and other institutional investors own 54.58% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Bellicum Pharmaceuticals (BLCM) Rating Increased to Buy at BidaskClub” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/04/16/bellicum-pharmaceuticals-blcm-rating-increased-to-buy-at-bidaskclub.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.